- Home
- HTD vs TRVI Comparison
HTD vs TRVI Comparison
Compare HTD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTD
- TRVI
- Stock Information
- Founded
- HTD 2004
- TRVI 2011
- Country
- HTD United States
- TRVI United States
- Employees
- HTD N/A
- TRVI N/A
- Industry
- HTD Finance Companies
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- HTD Finance
- TRVI Health Care
- Exchange
- HTD Nasdaq
- TRVI Nasdaq
- Market Cap
- HTD 868.1M
- TRVI 725.7M
- IPO Year
- HTD N/A
- TRVI 2019
- Fundamental
- Price
- HTD $24.51
- TRVI $8.66
- Analyst Decision
- HTD
- TRVI Strong Buy
- Analyst Count
- HTD 0
- TRVI 9
- Target Price
- HTD N/A
- TRVI $20.72
- AVG Volume (30 Days)
- HTD 92.3K
- TRVI 2.8M
- Earning Date
- HTD 01-01-0001
- TRVI 11-05-2025
- Dividend Yield
- HTD 8.59%
- TRVI N/A
- EPS Growth
- HTD N/A
- TRVI N/A
- EPS
- HTD N/A
- TRVI N/A
- Revenue
- HTD N/A
- TRVI N/A
- Revenue This Year
- HTD N/A
- TRVI N/A
- Revenue Next Year
- HTD N/A
- TRVI N/A
- P/E Ratio
- HTD N/A
- TRVI N/A
- Revenue Growth
- HTD N/A
- TRVI N/A
- 52 Week Low
- HTD $16.17
- TRVI $2.36
- 52 Week High
- HTD $22.13
- TRVI $9.83
- Technical
- Relative Strength Index (RSI)
- HTD 52.92
- TRVI 59.58
- Support Level
- HTD $24.40
- TRVI $6.93
- Resistance Level
- HTD $24.70
- TRVI $9.92
- Average True Range (ATR)
- HTD 0.14
- TRVI 0.71
- MACD
- HTD -0.02
- TRVI 0.19
- Stochastic Oscillator
- HTD 57.71
- TRVI 57.86
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.